scispace - formally typeset
M

Mona Saraiya

Researcher at Centers for Disease Control and Prevention

Publications -  258
Citations -  18861

Mona Saraiya is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Cervical cancer & Population. The author has an hindex of 57, co-authored 247 publications receiving 15391 citations. Previous affiliations of Mona Saraiya include American Society for Clinical Pathology.

Papers
More filters
Journal ArticleDOI

Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012.

Meg Watson, +10 more
- 01 Oct 2017 - 
TL;DR: In this article, the authors analyzed population-based rates of high-grade cervical cancer precursor lesions using data from four central cancer registries (diagnosis years 2009-2012 from Louisiana, Kentucky, Michigan, and diagnosis years 2011 -2012 from Los Angeles) by age, race, and histology.
Journal ArticleDOI

Trends in the occurrence of high‐grade anal intraepithelial neoplasia in San Francisco: 2000‐2009

Edgar P. Simard, +5 more
- 01 Oct 2013 - 
TL;DR: Although screening of human immunodeficiency virus (HIV)‐positive individuals for anal intraepithelial neoplasia (AIN) has been practiced in San Francisco among HIV health care providers since the early 1990s, to the authors' knowledge no study to date has focused on evaluating recent AIN trends.
Journal ArticleDOI

Current Cervical Cancer Screening Knowledge, Awareness, and Practices Among U.S. Affiliated Pacific Island Providers: Opportunities and Challenges

Julie S. Townsend, +5 more
- 01 Apr 2014 - 
TL;DR: Although cervical cancer screening is a priority in clinical practice, beliefs about annual screening, costs associated with screening, and varying levels of support for alternative screening tests pose barriers to providers throughout the USAPIJ.
Journal ArticleDOI

Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States

Harrell W. Chesson, +4 more
- 20 May 2019 - 
TL;DR: It is found that applying the current cancer cost estimates had a notable impact on the estimated medical costs averted by HPV vaccination over an extended time frame (100 years), and a moderate impact onThe estimated cost per quality-adjusted life year (QALY) gained by HPVvaccination.
Journal ArticleDOI

Establishing Baseline Cervical Cancer Screening Coverage - India, 2015-2016.

Elizabeth A. Van Dyne, +9 more
- 11 Jan 2019 - 
TL;DR: Prevalence of screening was higher among women with higher levels of education and household wealth, those who had ever been married, and urban residents, and this screening prevalence can be used as a baseline indicator for cervical cancer screening in India during state-based programmatic rollout and program evaluation.